4.5 Article

Hearing screening in newborns: systematic review of accuracy, effectiveness, and effects of interventions after screening

期刊

ARCHIVES OF DISEASE IN CHILDHOOD
卷 95, 期 2, 页码 130-135

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/adc.2008.151092

关键词

-

向作者/读者索取更多资源

Background: The authors aimed to evaluate the benefits and harms of universal newborn hearing screening programmes in the detection of hearing impairment. Objectives: In the absence of randomised trials evaluating whole screening programmes, the study divided the objective into three systematic reviews of non-randomised controlled studies of diagnostic accuracy of screening tests, screening versus no screening, and therapeutic effect of early versus later treatment. Methods: The authors searched 11 bibliographic databases, and included 17 studies (diagnostic: 9, screening: 2, and treatment: 6). All studies apart from one treatment study showed major quality deficits. Eight diagnostic studies comparing otoacoustic emissions with auditory brainstem response showed sensitivities (and specificities) between 50% (49.1%) and 100% (97.2%). Results: The studies comparing screening versus no screening showed an improvement of speech development of children in the screening group compared with the group without screening. Early treatment was associated with better language development in comparison to children with later treatment. Conclusions: The authors concluded that there is a lack of high-quality evidence regarding all elements of newborn hearing screening. Early identification and early treatment of children with hearing impairments may be associated with advantages in language development. Other patient-relevant parameters, such as social aspects, quality of life, and educational development, have not been adequately investigated.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, General & Internal

PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration

Karel G. M. Moons, Robert F. Wolff, Richard D. Riley, Penny F. Whiting, Marie Westwood, Gary S. Collins, Johannes B. Reitsma, Jos Kleijnen, Sue Mallett

ANNALS OF INTERNAL MEDICINE (2019)

Article Medicine, General & Internal

PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies

Robert F. Wolff, Karel G. M. Moons, Richard D. Riley, Penny F. Whiting, Marie Westwood, Gary S. Collins, Johannes B. Reitsma, Jos Kleijnen, Sue Mallett, Doug Altman, Patrick Bossuyt, Nancy R. Cook, Gennaro D'Amico, Thomas P. A. Debray, Jon Deeks, Joris de Groot, Emanuele di Angelantonio, Tom Fahey, Frank Harrell, Jill A. Hayden, Martijn W. Heymans, Lotty Hooft, Chris Hyde, John Ioannidis, Alfonso Iorio, Stephen Kaptoge, Andre Knottnerus, Mariska Leeflang, Frances Nixon, Pablo Perel, Bob Phillips, Heike Raatz, Rob Riemsma, Maroeska Rovers, Anne W. S. Rutjes, Willi Sauerbrei, Stefan Sauerland, Fueloep Scheibler, Rob Scholten, Ewoud Schuit, Ewout Steyerberg, Toni Tan, Gerben ter Riet, Danielle van der Windt, Yvonne Vergouwe, Andrew Vickers, Angela M. Wood

ANNALS OF INTERNAL MEDICINE (2019)

Review Economics

Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Willem J. A. Witlox, Antoinette D. I. van Asselt, Robert Wolff, Nigel Armstrong, Gill Worthy, Annette Chalker, Titas Buksnys, Lisa Stirk, Jos Kleijnen, Manuela A. Joore, Sabine E. Grimm

PHARMACOECONOMICS (2020)

Review Medicine, General & Internal

Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal

Laure Wynants, Ben Van Calster, Gary S. Collins, Richard D. Riley, Georg Heinze, Ewoud Schuit, Elena Albu, Banafsheh Arshi, Vanesa Bellou, Marc M. J. Bonten, Darren L. Dahly, Johanna A. Damen, Thomas P. A. Debray, Valentijn M. T. de Jong, Maarten De Vos, Paula Dhiman, Joie Ensor, Shan Gao, Maria C. Haller, Michael O. Harhay, Liesbet Henckaerts, Pauline Heus, Jeroen Hoogland, Mohammed Hudda, Kevin Jenniskens, Michael Kammer, Nina Kreuzberger, Anna Lohmann, Brooke Levis, Kim Luijken, Jie Ma, Glen P. Martin, David J. McLernon, Constanza L. Andaur Navarro, Johannes B. Reitsma, Jamie C. Sergeant, Chunhu Shi, Nicole Skoetz, Luc J. M. Smits, Kym I. E. Snell, Matthew Sperrin, Rene Spijker, Ewout W. Steyerberg, Toshihiko Takada, Ioanna Tzoulaki, Sander M. J. van Kuijk, Bas C. T. van Bussel, Iwan C. C. van der Horst, Kelly Reeve, Florien S. van Royen, Jan Y. Verbakel, Christine Wallisch, Jack Wilkinson, Robert Wolff, Lotty Hooft, Karel G. M. Moons, Maarten van Smeden

BMJ-BRITISH MEDICAL JOURNAL (2020)

Article Medicine, General & Internal

Challenges and Controversies in the Surgical Treatment of Cervical Cancer: Open Radical Hysterectomy versus Minimally Invasive Radical Hysterectomy

Jona Roeseler, Robert Wolff, Dirk O. Bauerschlag, Nicolai Maass, Peter Hillemanns, Helder Ferreira, Marie Debrouwere, Fueloep Scheibler, Friedemann Geiger, Mohamed Elessawy

Summary: This study systematically assessed disease-free survival, overall survival, and morbidity rates after surgical treatment for early-stage cervical cancer and discussed the impact of the LACC trial on clinical routine. The LACC trial found higher disease progression and recurrence rates with minimally invasive surgery compared to open radical hysterectomy, but there were conflicting results and opinions from other studies. More randomized controlled trials are needed to determine the most suitable treatment for early-stage cervical cancer.

JOURNAL OF CLINICAL MEDICINE (2021)

Article Medical Informatics

A scattered landscape: assessment of the evidence base for 71 patient decision aids developed in a hospital setting

Marion Danner, Marie Debrouwere, Anne Rummer, Kai Wehkamp, Jens Ulrich Rueffer, Friedemann Geiger, Robert Wolff, Karoline Weik, Fueloep Scheibler

Summary: This study aims to describe the development process of patient decision aids and evaluate the quality of identified evidence. The study found that despite careful evidence evaluation and summarization, the quality of identified evidence was generally poor and faced various challenges.

BMC MEDICAL INFORMATICS AND DECISION MAKING (2022)

Review Economics

Mogamulizumab for Previously Treated Mycosis Fungoides and Sezary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Sabine E. Grimm, Willem Witlox, Robert Wolff, Annette Chalker, Mickael Hiligsmann, Ben Wijnen, Charlotte Ahmadu, Steve Ryder, Nigel Armstrong, Steven Duffy, Isabel Syndikus, Jos Kleijnen, Manuela A. Joore

Summary: The National Institute for Health and Care Excellence (NICE) did not recommend the use of mogamulizumab for treating adults with mycosis fungoides (MF) or Sezary syndrome (SS) who have had at least one previous systemic treatment.

PHARMACOECONOMICS (2022)

Article Medicine, General & Internal

QUAPAS: An Adaptation of the QUADAS-2 Tool to Assess Prognostic Accuracy Studies

Jenny Lee, Frits Mulder, Mariska Leeflang, Robert Wolff, Penny Whiting, Patrick M. Bossuyt

Summary: Prognostic tests evaluate the probable course of a disease and future outcomes. QUAPAS is an adaptation of QUADAS-2 for evaluating bias and applicability in prognostic accuracy studies. The evaluation of prognostic accuracy studies includes assessment of bias and applicability in domains such as participants, index test, outcome, flow and timing, and analysis.

ANNALS OF INTERNAL MEDICINE (2022)

Review Medicine, General & Internal

Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis: a systematic review and meta-analysis

Stephanie Louise Swift, Thomas Puehler, Kate Misso, Shona Helen Lang, Carol Forbes, Jos Kleijnen, Marion Danner, Christian Kuhn, Assad Haneya, Hatim Seoudy, Jochen Cremer, Norbert Frey, Georg Lutter, Robert Wolff, Fueloep Scheibler, Kai Wehkamp, Derk Frank

Summary: The study compared the benefits and risks of TAVI and SAVR, finding that TAVI may reduce the risk of certain side effects while SAVR may reduce the risk of others. More data is needed to assess the long-term effects for low-risk patients, therefore every SAS patient should engage in SDM to make personalized decisions based on the benefits and risks of each treatment.

BMJ OPEN (2021)

Review Health Care Sciences & Services

Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis

Nigel Armstrong, Nasuh Buyukkaramikli, Hannah Penton, Rob Riemsma, Pim Wetzelaer, Vanesa Huertas Carrera, Stephanie Swift, Thea Drachen, Heike Raatz, Steve Ryder, Dhwani Shah, Titas Buksnys, Gill Worthy, Steven Duffy, Maiwenn Al, Jos Kleijnen

HEALTH TECHNOLOGY ASSESSMENT (2020)

Review Clinical Neurology

A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis

Gavin Giovannoni, Shona Lang, Robert Wolff, Steven Duffy, Robert Hyde, Elizabeth Kinter, Craig Wakeford, Maria Pia Sormani, Jos Kleijnen

NEUROLOGY AND THERAPY (2020)

Review Clinical Neurology

Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis

Maria Pia Sormani, Robert Wolff, Shona Lang, Steven Duffy, Robert Hyde, Elizabeth Kinter, Craig Wakeford, Gavin Giovannoni, Jos Kleijnen

NEUROLOGY AND THERAPY (2020)

Review Medicine, General & Internal

Percutaneous ethanol injection for liver metastases

Mateusz J. Swierz, Dawid Storman, Robert P. Riemsma, Robert Wolff, Jerzy W. Mitus, Michal Pedziwiatr, Jos Kleijnen, Malgorzata M. Bala

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)

Review Medicine, General & Internal

Electrocoagulation for liver metastases

Dawid Storman, Mateusz J. Swierz, Robert P. Riemsma, Robert Wolff, Jerzy W. Mitus, Michal Pedziwiatr, Jos Kleijnen, Malgorzata M. Bala

Summary: Evidence on the benefits and harms of using electrocoagulation alone or in combination with allopurinol or dimethyl sulfoxide in people with liver metastases is insufficient, based on one randomized clinical trial with low to very low certainty. It is very uncertain whether there is a difference in overall mortality and post-operative mortality between electrocoagulation alone and control.

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2021)

Review Medicine, General & Internal

Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases

Mateusz J. Swierz, Dawid Storman, Robert P. Riemsma, Robert Wolff, Jerzy W. Mitus, Michal Pedziwiatr, Jos Kleijnen, Malgorzata M. Bala

COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2020)

暂无数据